Published in Dalton Trans on July 02, 2010
Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J Am Chem Soc (2013) 0.91
Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Organometallics (2010) 0.89
Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Inorg Chem (2013) 0.85
Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands. Organometallics (2015) 0.76
Metal complexes in cancer therapy - an update from drug design perspective. Drug Des Devel Ther (2017) 0.75
Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction. Sci Rep (2017) 0.75
Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. Front Chem (2013) 0.75
A comparative DFT study on aquation and nucleobase binding of ruthenium (II) and osmium (II) arene complexes. J Mol Model (2013) 0.75
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med (2012) 1.78
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem (2006) 1.77
Efficient dehydrogenation of formic acid using an iron catalyst. Science (2011) 1.71
Antitumour metal compounds: more than theme and variations. Dalton Trans (2007) 1.64
Bioorganometallic chemistry--from teaching paradigms to medicinal applications. Chem Soc Rev (2008) 1.64
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev (2006) 1.55
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J Med Chem (2009) 1.51
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem (2005) 1.35
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem (2009) 1.32
From dysfunction to bis-function: on the design and applications of functionalised ionic liquids. Chemistry (2006) 1.31
Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity. Inorg Chem (2007) 1.30
Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med (2014) 1.27
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers (2008) 1.27
Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. Inorg Chem (2003) 1.25
Ionic solid-state dimers and polymers derived from imidazolium dicarboxylic acids. Chemistry (2006) 1.22
Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem (2007) 1.19
Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials (2009) 1.19
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol (2008) 1.18
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc (2005) 1.17
The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem (2008) 1.11
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans (2006) 1.10
The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells. Angew Chem Int Ed Engl (2008) 1.10
Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations. Arch Toxicol (2011) 1.10
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
Brønsted acidic ionic liquids and their zwitterions: synthesis, characterization and pKa determination. Chemistry (2004) 1.09
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J Med Chem (2007) 1.09
Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem (2007) 1.08
An internal fluorescent probe based on anthracene to evaluate cation-anion interactions in imidazolium salts. Chemistry (2010) 1.07
Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. J Inorg Biochem (2007) 1.06
Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents. Dalton Trans (2010) 1.05
Revisiting the electronic structure of phosphazenes. Inorg Chem (2005) 1.05
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. J Inorg Biochem (2010) 1.04
Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. Inorg Chem (2011) 1.04
Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem (2007) 1.03
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. J Biol Inorg Chem (2010) 1.03
Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential. J Biol Inorg Chem (2012) 1.03
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorg Chem (2006) 1.02
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett (2005) 1.01
Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J Inorg Biochem (2007) 1.01
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom (2009) 1.01
Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans (2009) 1.00
Gallium in cancer treatment. Curr Top Med Chem (2004) 0.98
A well-defined iron catalyst for the reduction of bicarbonates and carbon dioxide to formates, alkyl formates, and formamides. Angew Chem Int Ed Engl (2010) 0.98
Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Biochem (2011) 0.98
NMR, PGSE diffusion, and X-ray diffraction studies of lithium and potassium salts derived from diphenylphosphino(o-cyanophenyl)aniline and their crown ether complexes. Inorg Chem (2005) 0.97
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem (2005) 0.97
Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone. J Inorg Biochem (2002) 0.97
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J Med Chem (2011) 0.97
A viable hydrogen-storage system based on selective formic acid decomposition with a ruthenium catalyst. Angew Chem Int Ed Engl (2008) 0.96